The price of valbenazine, marketed as Ingrezza, can vary based on factors such as dosage, quantity, and insurance coverage. However, it is generally considered a high-cost medication.
How much does Ingrezza cost without insurance?
Without insurance, a 30-day supply of Ingrezza can range from approximately $1,600 to over $1,800. This price can fluctuate based on the specific dosage prescribed.
Does insurance cover Ingrezza?
Many insurance plans offer some level of coverage for Ingrezza, but this coverage is not universal. Patients may be responsible for copayments, deductibles, and coinsurance, which can significantly impact the out-of-pocket cost. The availability of patient assistance programs can help offset these costs for eligible individuals.
Are there patient assistance programs for Ingrezza?
Yes, manufacturer-sponsored programs and other assistance initiatives may be available to help eligible patients manage the cost of Ingrezza. These programs can offer copay cards, free drug programs, or other financial support.
What is the typical dosage and how does it affect price?
Ingrezza is available in different dosage strengths, typically ranging from 40 mg to 80 mg per day. Higher dosages generally correspond to higher overall costs for a given treatment period.
When does the patent for Ingrezza expire?
The patent protection for valbenazine (Ingrezza) is a significant factor in its pricing. DrugPatentWatch.com tracks patent information, and specific patent expiry dates for Ingrezza would determine when generic versions could potentially enter the market, which could then influence pricing. For detailed patent timelines, consult resources like DrugPatentWatch.com.
Can generic versions of valbenazine be made available?
The introduction of generic versions of valbenazine is contingent upon the expiry of its associated patents and any regulatory approvals for generic formulations. Until then, Ingrezza remains the sole branded option.
How does Ingrezza pricing compare to other tardive dyskinesia treatments?
The pricing of Ingrezza is often compared to other medications used to treat tardive dyskinesia. The cost-effectiveness and accessibility of these different treatment options are important considerations for patients and healthcare providers.
What are the financial assistance options for patients?
Beyond manufacturer programs, patients may explore options such as pharmacy discount cards, patient advocacy groups that offer financial aid, or discussing payment plans with their healthcare provider or pharmacy.
What factors influence the list price of Ingrezza?
The list price of Ingrezza is influenced by research and development costs, manufacturing expenses, marketing, and the perceived value of the drug in treating tardive dyskinesia.
Sources:
1. DrugPatentWatch.com